Home > News > Abraxis BioScience Announces Co-Promotion with AstraZeneca
April 27th, 2006
Abraxis BioScience Announces Co-Promotion with AstraZeneca
Abstract:
Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company, today announced they have entered into an agreement with AstraZeneca (NYSE:AZN) for the co-promotion of Abraxis' proprietary drug ABRAXANE(R), in the United States for a term of five and a half years.
Source:
Abraxis BioScience
Related News Press |
Nanomedicine
Diamond glitter: A play of colors with artificial DNA crystals May 17th, 2024
Advances in priming B cell immunity against HIV pave the way to future HIV vaccines, shows quartet of new studies May 17th, 2024
New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024
Announcements
Diamond glitter: A play of colors with artificial DNA crystals May 17th, 2024
Finding quantum order in chaos May 17th, 2024
Oscillating paramagnetic Meissner effect and Berezinskii-Kosterlitz-Thouless transition in cuprate superconductor May 17th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||